Track Satsuma Pharmaceuticals's total revenue ($0) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Mar 2023
Trailing 12 months ending Mar 2023
As of the most recent data (March 2023), STSA shows a total revenue of $0. In the prior-year period, the figure was $0. That is below the Healthcare sector average of $110B. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, STSA's total revenue is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Satsuma Pharmaceuticals is outperforming or lagging.
The Healthcare sector average total revenue is about $110B. Satsuma Pharmaceuticals is at $0, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how STSA stacks up against individual peers as well.
Tracking STSA's total revenue over time shows whether Satsuma Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this total revenue page, Stockcircle has Satsuma Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total revenue (currently $0) with ownership activity and broader fundamentals.